Qilu Pharma Spain

Qilu Pharma Spain company information, Employees & Contact Information

Qilu Pharma Spain is the European subsidiary of Qilu Pharmaceutical Co., one of the leading pharmaceutical companies in China, focuses on the research and development, manufacturing and marketing of generics and biosimilars, both of active pharmaceutical ingredients and finished dosage forms in several therapeutical areas. The company has eleven manufacturing sites and several research sites over a total surface area of 2.8 km2, in which 40,000 employees work (a large percentage of them are highly qualified). Qilu Pharmaceutical has over 200 products between active pharmaceutical ingredients and finished dosage forms with presence in 50 countries throughout Europe, United States, Australia, Latin America, Middle East, Africa and Asia Our mission is to develop and provide high quality medicines to improve the quality of life of patients, providing medical professionals with drugs produced using the most advanced technologies and applying the most rigorous quality standards.

Company Details

Employees
19
Founded
-
Address
Paseo De La Castellana, 40 8º,spain
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Madrid, Madrid
Looking for a particular Qilu Pharma Spain employee's phone or email?

Qilu Pharma Spain Questions

News

Sagent and Qilu Announce Strategic Collaboration to Expand Access to Critical Injectables in U.S. - PR Newswire

Sagent and Qilu Announce Strategic Collaboration to Expand Access to Critical Injectables in U.S. PR Newswire

Minghui and Qilu Pharmaceutical to advance MHB088C in Greater China - Pharmaceutical Technology

Minghui and Qilu Pharmaceutical to advance MHB088C in Greater China Pharmaceutical Technology

Minghui Pharma announces oncology agreement worth $185 M with Qilu Pharma in Greater China - BioSpectrum Asia

Minghui Pharma announces oncology agreement worth $185 M with Qilu Pharma in Greater China BioSpectrum Asia

Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting - PR Newswire

Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting PR Newswire

Chinese Company Qilu Pharmaceutical Is Supplying the Anti-Cancer Drug Cisplatin Injection to the United States Again - Yahoo Finance

Chinese Company Qilu Pharmaceutical Is Supplying the Anti-Cancer Drug Cisplatin Injection to the United States Again Yahoo Finance

FDA clears more chemotherapy imports from China's Qilu amid shortage of key cancer meds - Fierce Pharma

FDA clears more chemotherapy imports from China's Qilu amid shortage of key cancer meds Fierce Pharma

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy - Labiotech.eu

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy Labiotech.eu

Arbutus regains China rights to potential functional hep B cure as part of strategic rethink - Fierce Biotech

Arbutus regains China rights to potential functional hep B cure as part of strategic rethink Fierce Biotech

Pfizer & Astellas Sue Qilu Pharma Over Xtandi - NAVLIN DAILY

Pfizer & Astellas Sue Qilu Pharma Over Xtandi NAVLIN DAILY

EC approval of ranibizumab biosimilar Rimmyrah - Generics and Biosimilars Initiative

EC approval of ranibizumab biosimilar Rimmyrah Generics and Biosimilars Initiative

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023 - BioSpace

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023 BioSpace

Arbutus and Qilu Pharmaceutical Enter into an Exclusive - GlobeNewswire

Arbutus and Qilu Pharmaceutical Enter into an Exclusive GlobeNewswire

Shanghai Qilu Pharmaceutical Research and Development Centre describes new IRAK-4 degradation inducers - BioWorld MedTech

Shanghai Qilu Pharmaceutical Research and Development Centre describes new IRAK-4 degradation inducers BioWorld MedTech

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting - BioSpace

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting BioSpace

FDA to allow temporary overseas production to shore up supplies of chemo drug - Fierce Pharma

FDA to allow temporary overseas production to shore up supplies of chemo drug Fierce Pharma

Cend Therapeutics and Qilu Pharmaceutical Announce Partnership - GlobeNewswire

Cend Therapeutics and Qilu Pharmaceutical Announce Partnership GlobeNewswire

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024 - PR Newswire

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024 PR Newswire

Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress - BioSpace

Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress BioSpace

Fierce Pharma Asia—Pfizer partner's trial win; Roche's $300M China plant; Hengrui's HK IPO plan - Fierce Pharma

Fierce Pharma Asia—Pfizer partner's trial win; Roche's $300M China plant; Hengrui's HK IPO plan Fierce Pharma

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer - PR Newswire

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer PR Newswire

Warminster Biopharma Firm Ends $285M Licensing Deal with Chinese Company - BUCKSCO.Today

Warminster Biopharma Firm Ends $285M Licensing Deal with Chinese Company BUCKSCO.Today

Rimmyrah Joins Roster of Lucentis Biosimilars Awaiting Reimbursement in Italy - NAVLIN DAILY

Rimmyrah Joins Roster of Lucentis Biosimilars Awaiting Reimbursement in Italy NAVLIN DAILY

Qilu starts phase III trial for denosumab copy biological - Generics and Biosimilars Initiative

Qilu starts phase III trial for denosumab copy biological Generics and Biosimilars Initiative

Biosimilars thrive as China’s biotech industry gains momentum - Generics and Biosimilars Initiative

Biosimilars thrive as China’s biotech industry gains momentum Generics and Biosimilars Initiative

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy - Indian Pharma Post

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy Indian Pharma Post

Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic - Reuters

Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic Reuters

Arbutus terminates potential $285M licensing deal with Chinese drug company - The Business Journals

Arbutus terminates potential $285M licensing deal with Chinese drug company The Business Journals

NPC deputy Li Yan introduces Qilu Pharmaceutical to foreign media - 闪电新闻

NPC deputy Li Yan introduces Qilu Pharmaceutical to foreign media 闪电新闻

ECI Pharmaceuticals LLC Signs Agreement to Be Exclusive U.S. Distributor of Generic Cialis® - GlobeNewswire

ECI Pharmaceuticals LLC Signs Agreement to Be Exclusive U.S. Distributor of Generic Cialis® GlobeNewswire

10 killed in explosion at Chinese pharma plant - Fierce Pharma

10 killed in explosion at Chinese pharma plant Fierce Pharma

Astellas, Pfizer Sue to Block Copies of Lucrative Xtandi Drug - Bloomberg Law News

Astellas, Pfizer Sue to Block Copies of Lucrative Xtandi Drug Bloomberg Law News

China Approves Generic Nplate - NAVLIN DAILY

China Approves Generic Nplate NAVLIN DAILY

US FDA to temporarily import Chinese cancer drug to ease shortage - Business Standard

US FDA to temporarily import Chinese cancer drug to ease shortage Business Standard

China likes what it sees in Boston biotech - The Boston Globe

China likes what it sees in Boston biotech The Boston Globe

S. Korea's Peptron licenses global development of ADCs for cancer treatment - BioSpectrum Asia

S. Korea's Peptron licenses global development of ADCs for cancer treatment BioSpectrum Asia

Top Qilu Pharma Spain Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant